A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This study is prospective ,open-label, single-center phase II clinical study. Target
population is patients with advanced (stage III-IV) ovarian clear cell carcinoma. Study
objective is to evaluate effectiveness response of Camrelizumab + anlotinib in subjects with
advanced ovarian clear cell carcinoma Camrelizumab is a humanized anti-PD1 IgG4 monoclonal
antibody.